Share on StockTwits

Investment analysts at FBR Capital Markets assumed coverage on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) in a note issued to investors on Friday, reports. The firm set an “underperform” rating and a $172.00 price target on the stock. FBR Capital Markets’ target price points to a potential downside of 44.09% from the stock’s previous close.

A number of other firms have also recently commented on ICPT. Analysts at TheStreet upgraded shares of Intercept Pharmaceuticals to a “hold” rating in a research note on Thursday. Separately, analysts at Nomura upgraded shares of Intercept Pharmaceuticals to a “positive” rating in a research note on Tuesday. They now have a $456.00 price target on the stock, up previously from $323.00. Finally, analysts at RBC Capital raised their price target on shares of Intercept Pharmaceuticals from $425.00 to $500.00 in a research note on Tuesday. They now have an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. Intercept Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $472.91.

In other Intercept Pharmaceuticals news, CEO Mark Pruzanski unloaded 10,000 shares of the stock on the open market in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $226.72, for a total transaction of $2,267,200.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 296.36 on Friday. Intercept Pharmaceuticals has a 52-week low of $42.41 and a 52-week high of $497.00. The stock has a 50-day moving average of $234.8 and a 200-day moving average of $291.9. The company’s market cap is $6.249 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.79) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.12) by $0.67. The company had revenue of $405.40 million for the quarter, compared to the consensus estimate of $400.00 million. Analysts expect that Intercept Pharmaceuticals will post $-13.81 EPS for the current fiscal year.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.